Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Cisapride vs placebo

Adverse effects (participant interviews) · adults and children with cystic fibrosis

1 finding from 1 review

Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Cisapride vs placebo

Total gastrointestinal symptom scores (participant‐reported symptom scores from 20 to 100) · adults and children with cystic fibrosis

1 finding from 1 review

Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 17 participants
Very low

Cisapride vs placebo

Hospitalisation (any cause) · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cisapride vs placebo

Hospitalisation for DIOS · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cisapride vs placebo

Quality of life · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cisapride vs placebo

Tolerability · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for preventing distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes

Time taken from start of treatment until the resolution of DIOS · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes

Treatment failure rate · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes

Adherence · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes

Episodes of acute DIOS · adults and children with cystic fibrosis

1 finding from 1 review

Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes

Adverse effects: abdominal mass · adults and children with cystic fibrosis

1 finding from 1 review

Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes

Abdominal pain · adults and children with cystic fibrosis

1 finding from 1 review

Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Summary of findings ‐ AZLI vs placebo

FEV1 % predicted: relative change from baseline · adults and children with CF

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 99 participants
Moderate

Summary of findings ‐ AZLI vs placebo

Time to next exacerbation · adults and children with CF

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 100 participants
Moderate

Summary of findings ‐ AZLI vs placebo

Participants hospitalised for respiratory exacerbation · adults and children with CF

Summary of findings ‐ AZLI showed no clear difference in participants hospitalised for respiratory exacerbation compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 0.88 [0.53, 1.45]
1 study · 100 participants
Moderate

Summary of findings ‐ AZLI vs placebo

Adverse events (AEs) (1 or more events) · adults and children with CF

Summary of findings ‐ AZLI showed no clear difference in any AEs compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 1.08 [0.98, 1.19]
1 study · 100 participants
Moderate

Summary of findings ‐ AZLI vs placebo

All‐cause mortality · adults and children with CF

Summary of findings ‐ AZLI showed no clear difference in mortality compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic therapy for chronic infection with Burkholderia cepacia complex in people with cystic fibrosis 2021 · Cochrane Headline outcomes only
RR 5.41 [0.27, 109.87]
1 study · 100 participants
Moderate

Intervention not reported

Number of joint bleeding episodes per year (AJBR) · children or adults with hemophilia A or B

1 finding from 1 review

Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated… 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 219 participants
Low

Intervention not reported

Number of total bleeds per year (ABR) · children or adults with hemophilia A or B

1 finding from 1 review

Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated… 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 310 participants
Low

Intervention not reported

Treatment‐related adverse events · children or adults with hemophilia A or B

1 finding from 1 review

Clotting factor concentrates for preventing bleeding and bleeding‐related complications in previously treated… 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 223 participants
Very low